Striant and Testoderm, have patent expirations of August 23, 2019 and November 10, 2019, respectively. The National Institutes of Health states that approximately 5 million American men do not
produce enough of the hormoneXXXtype 2 diabetes using testosterone treatment as a preventative. The International Diabetes Federation has stated that the cost to treat type 2 diabetes worldwide now
hovers at 471 billion dollars